Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Mycobacterium Infections accounts for 1.9% share of global Infectious Disease clinical trial activity in 2020

24 Mar 2021 (Last Updated March 24th, 2021 14:16)

Mycobacterium Infections accounted for a 1.9% share of the global clinical trials within the Infectious Disease therapy area in 2020, registering a decrease of 2.1% when compared with the last ten-year average of 4.0% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Mycobacterium Infections

Industry sponsored trials held a 41.1% share of all the clinical trials for Mycobacterium Infections indication in 2020, registering an increase of 10.8% when compared with the ten-year average of 30.3%. Non-industry sponsored trials accounted for a 58.9% share in 2020, marking a decrease of 10.8% over the ten-year average of 69.7%.


  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Mycobacterium Infections trials

Asia-Pacific was the top region for industry sponsored Mycobacterium Infections trials, accounting for a 69.2% share in 2020, when compared with the five-year average of 59.8% and ten-year average of 47.3%.

Europe was at the second position with a 23.1% share in 2020, over the five-year average of 31.8% and ten-year average of 38.9%, followed by Middle East and Africa with a 12.8% share in 2020, as against five-year and ten-year averages of 22.2% and 22.4% respectively.

North America stood fourth with a 10.3% share in 2020, compared with the five-year average of 9.3% and ten-year average of 10.4%, followed by South and Central America with a 5.1% share in 2020, over five-year and ten-year averages of 10.3% and 6.9% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Mycobacterium Infections trials, accounting for a 51.3% share in 2020, as against the five-year average of 33.0% and ten-year average of 19.5%.

Russia held a 12.8% share in 2020, over the five-year average of 16.7% and ten-year average of 23.6%, followed by the US with a 10.3% share in 2020, compared with the five-year and ten-year averages of 7.2% and 8.6% respectively.

India held a 7.7% share in 2020, as against the five-year average of 7.5% and ten-year average of 7.8%.

South Africa held a 5.1% share in 2020, over the five-year and ten-year averages of 16.8% and 17.4% respectively.

Top regions of non-industry sponsored Mycobacterium Infections trials

Asia-Pacific was the top region for non-industry sponsored Mycobacterium Infections trials, accounting for a 51.0% share in 2020 when compared with the five-year average of 56.6% and ten-year average of 47.5%.

Middle East and Africa was at the second position with a 28.6% share in 2020, over the five-year and ten-year averages of 27.2% and 31.9% respectively, followed by North America with a 14.3% share in 2020, as against the five-year average of 10.9% and ten-year average of 11.1%.

Europe stood at the fourth position with a 14.3% share in 2020, compared with the five-year average of 17.1% and ten-year average of 18.5%, followed by South and Central America with a 6.1% share in 2020, over the five-year and ten-year averages of 7.3% and 5.7% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Mycobacterium Infections trials, accounting for a 24.5% share in 2020, as against the five-year average of 24.2% and ten-year average of 17.0%.

South Africa held a 16.3% share in 2020, over the five-year average of 17.1% and ten-year average of 18.2%, followed by the US with a 12.2% share, compared with the five-year and ten-year averages of 8.3% and 8.8% respectively.

Uganda held an 8.2% share in 2020, as against the five-year average of 6.5% and ten-year average of 6.0%.

The Netherlands held a 6.1% share in 2020, over the five-year average of 2.5% and ten-year average of 2.5%.

Phase I trials lead industry sponsored clinical trials for Mycobacterium Infections in 2020

Phase I trials held a 69.2% share of industry sponsored clinical trials for Mycobacterium Infections in 2020, over the five-year average of 57.8% and ten-year average of 55.4%.

Phase III trials held a 15.4% share in 2020, as against the five-year average of 15.0% and ten-year average of 15.8%. Phase II trials held a 10.3% share in 2020, compared with the five-year and ten-year averages of 18.4% and 20.0% respectively.

Phase IV trials held a 5.1% share in 2020, over the five-year average of 8.7% and ten-year average of 8.8%.

Phase II trials lead non-industry sponsored clinical trials for Mycobacterium Infections in 2020

Phase II trials held a 42.9% share of non-industry sponsored clinical trials for Mycobacterium Infections in 2020, over the five-year average of 43.5% and ten-year average of 41.8%.

Phase III trials held a 23.2% share in 2020, as against the five-year average of 19.5% and ten-year average of 18.6%. Phase IV trials held a 19.6% share, compared with the five-year and ten-year averages of 19.0% and 20.1% respectively.

Phase I trials held a 14.3% share in 2020, over the five-year average of 18.0% and ten-year average of 19.5%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.